foretinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued.   Wikipedia

Chemistry

  • SMILES: COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3F)ccnc2cc1OCCCN6CCOCC6
  • InChIKey: CXQHYVUVSFXTMY-UHFFFAOYSA-N
  • Mol. Mass: 632.66
  • ALogP: 5.77
  • ChEMBL Molecule:
    foretinib  
More Chemistry

Pharmacology

Alternative names

exel 2880 | exel-2880 | foretinib | gsk089 | gsk1363089 | gsk 1363089 | gsk-1363089 | gsk1363089g | xl 880 | xl-880 | xl880 cpd

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Renal Cell (Phase 2)

Head and Neck Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 2)

Lung Neoplasms (Phase 1/Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue